Susan Dana Jones

Susan Dana Jones, Ph.D. is currently Vice President and Senior Consultant with BioProcess Technology Consultants. She has more than 20 years of discovery, product development, and strategic planning experience in biotechnology. Dr. Jones's expertise spans the drug discovery and development spectrum, including antibody engineering, high-throughput discovery technologies, proteomics, gene therapy, and oncology. She co-founded two start-up biotechnology companies and has managed discovery and product development programs in multiple organizations and for multiple disease areas. Her current activities include managing outsourced biopharmaceutical process development activities for client product development programs, technical and medical evaluation of new product opportunities through physician interviews, literature review, and analysis, and evaluation of strategic options for expanding and utilizing existing products and technology platforms. Prior to joining BioProcess Technology Consultants, Dr. Jones was Senior Vice President of Corporate Development at Serenex, Inc, where she worked with other senior managers to complete a $15M Series B financing. She was previously Vice President of Product Development at Waratah Pharmaceuticals, where her responsibilities included management of outsourced product development and manufacturing activities for a combined protein and peptide therapeutics. As Vice President of Technology at Dyax Corp, she evaluated new technology and target acquisition opportunities, communicated Dyax technology and capabilities to investors and potential collaborators, and prepared documentation for public and private financing resulting in capital raises in excess of $100M. Before Dyax, Dr. Jones held research and development positions of increasing responsibility at Peptimed Inc., Virus Research Institute (now Avant Immunotherapeutics), and IntraImmune Therapies Inc. Dr. Jones received her Bachelor's degree from Harvard University, her Ph.D. from the University of California, San Francisco, and performed post-doctoral research at the Dana- Farber Cancer Institute of Harvard Medical School.